We are driven by the passion to nurture and preserve the precious moments of everyday life for all people, regardless of their health condition. From treatment to disease prevention, we will continue to develop innovative new drugs that contribute to better health and bring smiles to the faces of people everywhere.
Latest News
-
August 30, 2023
News Releases
Taiho Pharmaceutical Announces the Launch of FGFR Inhibitor LYTGOBI® Tablets 4mg in Japan
-
August 25, 2023
News Releases
Taiho Pharmaceutical and Phost'in Therapeutics Announce an Option and License Agreement on the First-in-Class GnT-V Inhibitor PhOx430（PDF：315.8 KB）
-
August 07, 2023
News Releases
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations（PDF：361.4 KB）
-
August 03, 2023
News Releases
FDA Approves LONSURF®(trifluridine/tipiracil)in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC)（PDF：418.4 KB）
-
August 01, 2023
News Releases
European Commission Approves LONSURF® (Trifluridine/tipiracil) in Combination With Bevacizumab
in 3rd Line Refractory Metastatic Colorectal Cancer (mCRC)
-
October 31, 2023
Information
Otsuka Holdings announces FY2023 3Q financial results
-
February 22, 2023
Information
Donations to Support Relief Efforts Following Earthquakes in Turkey and Syria
-
July 12, 2018
Information
Announcement of Support from Otsuka Holdings and Its Group Companies in the Aftermath of Severe Storms in Japan（PDF：165.9 KB）